MedTrace Logo

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

NCT03039101 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-10-07

No results posted yet for this study

Summary

The purpose of this study is to see if the recruitment of a certain cell type (the alpha 4 integrin (CD49d) expressing neutrophil) during a nasal allergen challenge can be inhibited by pretreatment with an FDA approved leukotriene antagonist (montelukast).

Conditions

  • Nasal Allergy

Interventions

PROCEDURE

Nasal lavage

determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry

PROCEDURE

Nasal allergen challenge

A small amount of allergen extract will be applied to one naris.

PROCEDURE

Epicutaneous skin testing

Skin testing (prick) to determine allergies.

PROCEDURE

Peripheral blood

Peripheral blood draw

DRUG

Montelukast 10Mg Tablet

one pill orally, daily, for 1 week

DRUG

Placebo Oral Tablet

one pill orally, daily, for 1 week

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Mitchell Grayson

    lead OTHER

Principal Investigators

  • Mitchell H Grayson, MD · Nationwide Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-06
Primary Completion
2018-07-16
Completion
2018-07-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03039101 on ClinicalTrials.gov